The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. BioNTech SE ADR shares valued at $3,021,000 were purchased by Richardson Ryan on Feb 27 ’25. At $114.00 per share, Richardson Ryan acquired 26,500 shares.
Also, Medine GmbH purchased 1,000,000 shares, netting a total of over 119,580,000 in proceeds.
Before that, Poetting Sierk had added 120,000 shares to its account. In a trade valued at $14,349,600, the Officer bought BioNTech SE ADR shares for $119.58 each.
As published in their initiating research note from Citigroup on March 13, 2025, BioNTech SE ADR [BNTX] has been a Buy and the price target has been revised to $145. Analysts at Truist started covering the stock with ‘”a Buy”‘ outlook in a report released in early January. As of December 11, 2024, Wells Fargo has initiated its “an Overweight” rating for BNTX. Earlier on December 02, 2024, BMO Capital Markets resumed its rating. Their recommendation was “an Outperform” for BNTX stock.
Analyzing BNTX Stock Performance
During the last five days, there has been a surge of approximately 15.99%. Over the course of the year, BioNTech SE ADR shares have jumped approximately 0.77%. Shares of the company reached a 52-week high of $129.27 on 01/07/25 and a 52-week low of $81.20 on 04/07/25. A 50-day SMA is recorded $103.52, while a 200-day SMA reached $105.64.
Support And Resistance Levels for BioNTech SE ADR (BNTX)
According to the 24-hour chart, there is a support level at 110.62, which, if violated, would cause prices to drop to 106.41. In the upper region, resistance lies at 119.68. The next price resistance is at 124.53. RSI (Relative Strength Index) is 68.48 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 10.18, which suggests the price will increase in the coming days. Percent R is at 14.03%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
